Many discontinue obesity medication – new study highlights the reasons

A new study maps out the most common reasons why patients choose to stop taking obesity medication prematurely. “Obesity medication discontinuation reverses hea...

New findings on the diseases that crushed Napoleon’s army

As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever d...

Venomaid's rapid test aims to find the right snake bite treatment

that claims countless lives, especially in tropical countries.

A cluster contribution to European life science innovation and competitiveness?

Mercodia AB

Astra Zeneca’s asthma drug nears approval for sinus inflammation

Astra Zeneca’s drug Tezspire receives positive opinion from the European Medicines Agency (EMA) for the treatment of chronic rhinosinusitis with nasal polyps.

IVDR Reality Check: Are We Moving Fast Enough?

As of February 2025, around 1,500 IVDR certificates have been issued. But if an estimated 18,700 devices still need certification before the 2029 deadline, then...

ZEISS EVO as the Key to Wire Technology in Modern Medicine

High-performance wires for stents.

Pfizer sänker priser i USA – fler bolag väntas följa efter

Läkemedelsjätten Pfizer är först ut med att utlova sänkta priser på receptbelagda läkemedel i USA efter en överenskommelse med Trumpadministrationen.

Phase III win for Hansa Biopharma: “We Are Thrilled”

Swedish biotech Hansa Biopharma’s transplant drug imlifidase has met the primary efficacy endpoint in a registration-enabling Phase III study in the United States.

Europeiska läkemedelsaktier rasar efter Trumps tullhot

Europeiska läkemedelsbolag faller kraftigt efter att USA:s president Donald Trump flaggat för att stora tullhöjningar är på gång mot branschen.

EMA och WHO tillbakavisar Trumps påståenden om autism

Såväl världshälsoorganisationen WHO som EU och hälsomyndigheter i Storbritannien vidhåller att det är säkert för gravida kvinnor att använda paracetamol, trots Donald Trumps påståenden på måndagen om en koppling till autism....

Efter Trumps utspel – FDA godkänner behandling för autism

Den amerikanska läkemedelsmyndigheten FDA har inlett en process för att godkänna leukovorin som behandling för vissa personer med autismsymtom.

Heart Monitoring in Breast Cancer – Essential or Excessive?

Trastuzumab and related drugs have transformed breast cancer treatment and dramatically improved survival rates. But the close cardiac monitoring required durin...

Astra Zeneca pauses multi-million investment in the UK

Astra Zeneca has paused a planned investment worth $270 million. It is the latest pharmaceutical company to pull back on its commitments in the UK.

Strategic Clarity: The New Currency in Life Science

In an industry shaped by rapid regulatory changes and global competition, leading life science companies are rethinking what it takes to succeed. Increasingly, ...

BMS planerar investera nära 400 miljarder i USA

Under måndagen meddelade Bristol Myers Squibb att bolaget planerar att investera 40 miljarder dollar, motsvarande 387 miljarder svenska kronor, i USA under de k...

How the Foreign Office will promote Swedish life science exports

The broadness and innovative strength keep Swedish life science exports strong, but the protectionist tendencies in the world are worrying, says Camilla Melland...

The Future of Metrology is Coming to Your Region

Join our event series.

US Health Secretary Kennedy dismisses all vaccine experts – assembles new committee

Robert F. Kennedy Jr. has dismissed all 17 members of the CDC’s vaccine advisory panel. A new group of experts will be appointed directly by the Health Secretar...

Genmab to Acquire Dutch biotech for USD 8 Billion

Danish pharmaceutical company Genmab has agreed to acquire Dutch firm Merus, a developer of cancer therapies, for USD 8 billion, equivalent to nearly SEK 75 billion.

The US is leaving the WHO

The newly installed US President, Donald Trump, has issued an executive order for the US to leave the World Health Organization, WHO.

After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...

Samuel Lagercrantz: ”Kommer TACO-Trumps tullavtal hålla?”

Olika bud om USA-tullar på läkemedel har skapat osäkerhet. Nu har en överenskommelse slutits, men med Donald Trump som president vet man inte säkert om den komm...